Scarica l'app Stockscreener
150.62
0.16%
0.24
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$150.38
Aprire:
$150.65
Volume 24 ore:
1.73M
Relative Volume:
1.04
Capitalizzazione di mercato:
$286.29B
Reddito:
$54.66B
Utile/perdita netta:
$13.58B
Rapporto P/E:
21.46
EPS:
7.0171
Flusso di cassa netto:
$16.05B
1 W Prestazione:
+4.78%
1M Prestazione:
+8.59%
6M Prestazione:
+0.59%
1 anno Prestazione:
+15.18%
Intervallo 1D:
$150.23
$151.74
Intervallo di 1 settimana:
$142.31
$151.83
Portata 52W:
$121.57
$170.46
Novartis Ag Adr Stock (NVS) Company Profile
Nome
Novartis Ag Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare NVS vs LLY, JNJ, ABBV, MRK
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
150.62 | 286.29B | 54.66B | 13.58B | 16.05B | 7.0171 |
LLY
Lilly Eli Co
|
1,257.03 | 1.12T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
255.56 | 615.87B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
285.42 | 504.37B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
145.95 | 360.08B | 65.51B | 8.93B | 14.12B | 3.5532 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-09-10 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2026-09-09 | Downgrade | Deutsche Bank | Buy → Hold |
| 2026-09-09 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2026-03-11 | Aggiornamento | Argus | Hold → Buy |
| 2026-01-27 | Iniziato | Citigroup | Buy |
| 2026-01-06 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2025-12-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-12-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-09-12 | Downgrade | Goldman | Neutral → Sell |
| 2025-08-08 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2025-02-13 | Downgrade | UBS | Buy → Neutral |
| 2025-02-12 | Iniziato | Morgan Stanley | Underweight |
| 2025-02-04 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-12-04 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-09-11 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-09-05 | Downgrade | Goldman | Buy → Neutral |
| 2024-09-03 | Downgrade | Jefferies | Buy → Hold |
| 2024-07-19 | Downgrade | Deutsche Bank | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-02-23 | Iniziato | BMO Capital Markets | Market Perform |
| 2024-01-23 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Ripresa | UBS | Buy |
| 2023-12-18 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-09-25 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-26 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2023-03-27 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2023-01-26 | Downgrade | Citigroup | Buy → Neutral |
| 2022-12-05 | Aggiornamento | Stifel | Hold → Buy |
| 2022-09-15 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2022-09-14 | Downgrade | Berenberg | Buy → Hold |
| 2022-05-09 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2022-01-10 | Ripresa | Citigroup | Buy |
| 2021-12-14 | Downgrade | Redburn | Buy → Neutral |
| 2021-12-06 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| 2021-12-03 | Downgrade | Bryan Garnier | Buy → Neutral |
| 2021-09-20 | Downgrade | Deutsche Bank | Hold → Sell |
| 2021-03-22 | Iniziato | Bernstein | Mkt Perform |
| 2021-03-10 | Downgrade | Argus | Buy → Hold |
| 2021-02-01 | Downgrade | Cowen | Outperform → Market Perform |
| 2021-01-15 | Iniziato | Deutsche Bank | Buy |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2020-09-10 | Aggiornamento | UBS | Neutral → Buy |
| 2020-09-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-15 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-03-10 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2020-02-25 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-04-25 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-04-25 | Aggiornamento | Liberum | Hold → Buy |
| 2019-04-10 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-01-02 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-12-11 | Ripresa | Jefferies | Buy |
| 2018-10-09 | Iniziato | Guggenheim | Neutral |
| 2018-09-10 | Aggiornamento | BofA/Merrill | Underperform → Buy |
| 2018-05-29 | Downgrade | HSBC Securities | Buy → Hold |
| 2018-05-25 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-01-25 | Reiterato | Leerink Partners | Outperform |
| 2017-12-06 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2017-07-26 | Aggiornamento | Morgan Stanley | Underweight → Overweight |
| 2017-07-05 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2017-03-09 | Iniziato | Liberum | Buy |
Mostra tutto
Novartis Ag Adr Borsa (NVS) Ultime notizie
Novartis wins Rhapsido approval as Bank of America keeps CHF 150 target for Novartis stock - ad-hoc-news.de
Novartis AG : RBC is Neutral - www.marketscreener.com
IgA Nephropathy Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences - StreetInsider
Novartis AG Stock (NVS) Moved Up by 3.00% on Oct 15: Drivers Behind the Movement - TradingKey
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AGNVS - PR Newswire
Novartis AG (NOT.F) Analyst Insights, Price Targets & RecommendationsYahoo Finance - Yahoo! Finance Canada
Genentech Wins Judge's OK Of $18M Novartis Award - Law360
Novartis AG (NVS) Stock Up 3.1% but GF Value Says Overvalued -- GF Score: 68/100 - GuruFocus
US biotech company enforces eye treatment award against Novartis - Global Arbitration Review
Why Novartis (NVS) Stock Is Up Today - Quiver Quantitative
Matchpoint Therapeutics Expands Leadership Team with Appointment of John O’Malley, M.D., Ph.D., as Chief Medical Officer - GlobeNewswire Inc.
Law firm probes Novartis over possible securities fraud after trial failure drops shares 14%. - Pluang
Community health takes a village: Screening in the barber’s chair - Novartis
Novartis AG NVSEF Stock Forecast & Price Target - Yahoo! Finance Canada
NOVARTIS AG N (NOT.HA) Q2 FY2026 earnings call transcript - Yahoo Finance
Novartis AG Rises Monday - Moomoo
Swiss Blue-chip Index Starts Week Upbeat; Roche, Novartis Shares Gain - marketscreener.com
Weekly Recap: Abogen mRNA T‑cell engager investment and Rhapsido approval - TradingView
Novartis AG (CEUX:1NOVNm) Stock PDF (Updated: 2026/10/10) - GuruFocus
Cancer Stocks to Consider as Oncology Innovation Accelerates - Zacks Investment Research
Novartis AG (NOVN.VI) income statement - Yahoo Finance UK
NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido - The Globe and Mail
Swiss Market Index Retreats; Novartis Shares Decline - marketscreener.com
NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido - Zacks Investment Research
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AGNVS - PR Newswire
Novartis achieves Tier 1 in the 2026 CCLA Corporate Mental Health Benchmark - Novartis
Novartis wins FDA approval for a form of chronic hives - marketscreener.com
Novartis AG (NOVN) Gets a Buy from Citi - The Globe and Mail
AI companies run virtual drug trials, aim to improve success of human studies - Reuters
Novartis AG (CEUX:1NOVNM) Cyclically Adjusted Price-to-FCF : (As of Oct. 07, 2026) - GuruFocus
US FDA expands use of Novartis drug for chronic skin condition - Reuters
Why Is Novartis Stock Trading Higher Today?Novartis (NYSE:NVS) - Benzinga
Novartis (NVS) Secures FDA Approval for Rhapsido, Expanding Trea - GuruFocus
Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU) - The Manila Times
Novartis Rhapsido® (remibrutinib) receives FDA approval as - GlobeNewswire
Novartis to Present Key Data on Multiple Sclerosis - marketscreener.com
Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026 - marketscreener.com
Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026 - GlobeNewswire Inc.
Novartis advances multiple sclerosis innovation with - GlobeNewswire
The patient who changed the course of my career - Novartis
Novartis AG (SWX: NOVN): Now September Has Ended, Is It Now Time To Buy? - Stocks Down Under
Novartis Sues Apotex Over Mekinist Copies, Tafinlar Drug Combo - Bloomberg Law News
Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal - Zacks Investment Research
Sironax Named to Fierce Biotech’s “Fierce 15” List of the Most Innovative and Promising Private Biotechs of 2026 - GlobeNewswire Inc.
BofA Expects Higher Q3 Sales From Novartis Amid Strong Key Growth Drivers - Moomoo
Should You Invest in the VanEck Pharmaceutical ETF (PPH)? - Zacks Investment Research
Total non-current liabilities of Novartis AG – BX:NOT - TradingView
NOVARTIS AG N (NOTA.F) Q2 FY2026 earnings call transcript - Yahoo Finance
Agios' Growth Story Hinges on Mitapivat's Commercial Expansion - Zacks Investment Research
Europe Cancer Metabolism Based Therapeutics Market Forecast to 2035 by Modality, Route, Indication, and Therapy Sales | 25.3% CAGR Drives an $8.54 Billion Opportunity - GlobeNewswire Inc.
Novartis Ag Adr Azioni (NVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Novartis Ag Adr Azioni (NVS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Marshall Fiona | Officer |
Feb 12 '26 |
Proposed Sale |
161.35 |
30,743 |
4,960,277 |
0 |
| Bulto Carulla Victor | Officer |
Feb 09 '26 |
Proposed Sale |
156.21 |
7,500 |
1,171,576 |
0 |
0.76%
0.52%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):